7,580.00

+5.50

+0.07%

52,106.00

-27.00

-0.05%

28,175.75

+48.25

+0.17%

Russell 2000 Futures

2,819.10

+1.30

+0.05%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,966.60

-3.00

-0.08%

77,103.25

-1,186.50

-1.52%

Crude Oil Dec 26

96.66

+0.20

+0.21%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqGM - Nasdaq Real Time Price USD

Veraxa Biotech AG (VRXA)

1.0300 -0.1100 (-9.65%)

At close: November 2 at 4:00:01 PM EST

1.0800 +0.0500 (+4.85%)

After hours: November 2 at 4:39:10 PM EST

Loading Chart for VRXA

Chart Range Bar

Interval:

In partnership with ChartIQ

VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline

VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline

VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

VERAXA Biotech (VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

This Tiny Biotech Stock Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

Veraxa Biotech stock gains on FDA-aligned testing strategy

Veraxa Biotech stock gains on FDA-aligned testing strategy

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress

VERAXA Biotech (VRXA) Advances Oncology Pipeline as Xlife Sciences Reports First-Half Progress

VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy

VERAXA Biotech (VRXA) Building a New Approach to Precision Cancer Therapy

Mobilize your Website

View Site in Mobile | Classic

Share by: